Christian Taverna1, Giovanni Martinelli2, Felicitas Hitz2, Walter Mingrone2, Thomas Pabst2, Lidija Cevreska2, Auro Del Giglio2, Anna Vanazzi2, Daniele Laszlo2, Johann Raats2, Daniel Rauch2, Daniel A Vorobiof2, Andreas Lohri2, Christine Biaggi Rudolf2, Stéphanie Rondeau2, Corinne Rusterholz2, Ingmar A F M Heijnen2, Emanuele Zucca2, Michele Ghielmini2. 1. Christian Taverna, Kantonsspital Münsterlingen, Münsterlingen; Felicitas Hitz, Kantonsspital St Gallen, St Gallen; Walter Mingrone, Kantonsspital Aarau/Olten, Olten; Thomas Pabst, Inselspital Bern; Christine Biaggi Rudolf, Stéphanie Rondeau, and Corinne Rusterholz, Swiss Group for Clinical Cancer Research SAKK, Bern; Daniel Rauch, Spital Thun Simmental, Thun; Andreas Lohri, Kantonsspital Liestal, Liestal; Ingmar A.F.M. Heijnen, University Hospital Basel, Basel; Emanuele Zucca and Michele Ghielmini, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Giovanni Martinelli, Anna Vanazzi, and Daniele Laszlo, Istituto Europeo di Oncologia, Milan, Italy; Lidija Cevreska, University Clinic for Hematology, Skopje, Macedonia; Auro del Giglio, ABC Fondation School of Medicine, Sao Paulo, Brazil; Johann Raats, Panorama Oncology Unit, Cape Town; and Daniel A. Vorobiof, Sandton Oncology Center, Johannesburg, South Africa. christian.taverna@stgag.ch. 2. Christian Taverna, Kantonsspital Münsterlingen, Münsterlingen; Felicitas Hitz, Kantonsspital St Gallen, St Gallen; Walter Mingrone, Kantonsspital Aarau/Olten, Olten; Thomas Pabst, Inselspital Bern; Christine Biaggi Rudolf, Stéphanie Rondeau, and Corinne Rusterholz, Swiss Group for Clinical Cancer Research SAKK, Bern; Daniel Rauch, Spital Thun Simmental, Thun; Andreas Lohri, Kantonsspital Liestal, Liestal; Ingmar A.F.M. Heijnen, University Hospital Basel, Basel; Emanuele Zucca and Michele Ghielmini, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Giovanni Martinelli, Anna Vanazzi, and Daniele Laszlo, Istituto Europeo di Oncologia, Milan, Italy; Lidija Cevreska, University Clinic for Hematology, Skopje, Macedonia; Auro del Giglio, ABC Fondation School of Medicine, Sao Paulo, Brazil; Johann Raats, Panorama Oncology Unit, Cape Town; and Daniel A. Vorobiof, Sandton Oncology Center, Johannesburg, South Africa.
Abstract
PURPOSE:Rituximab maintenance therapy has been shown to improve progression-free survival in patients with follicular lymphoma; however, the optimal duration of maintenance treatment remains unknown. PATIENTS AND METHODS: Two hundred seventy patients with untreated, relapsed, stable, or chemotherapy-resistant follicular lymphoma were treated with four doses of rituximab monotherapy in weekly intervals (375 mg/m(2)). Patients achieving at least a partial response were randomly assigned to receive maintenance therapy with one infusion of rituximab every 2 months, either on a short-term schedule (four administrations) or a long-term schedule (maximum of 5 years or until disease progression or unacceptable toxicity). The primary end point was event-free survival (EFS). Progression-free survival, overall survival (OS), and toxicity were secondary end points. Comparisons between the two arms were performed using the log-rank test for survival end points. RESULTS:One hundred sixty-five patients were randomly assigned to the short-term (n = 82) or long-term (n = 83) maintenance arms. Because of the low event rate, the final analysis was performed after 95 events had occurred, which was before the targeted event number of 99 had been reached. At a median follow-up period of 6.4 years, the median EFS was 3.4 years (95% CI, 2.1 to 5.3) in the short-term arm and 5.3 years (95% CI, 3.5 to not available) in the long-term arm (P = .14). Patients in the long-term arm experienced more adverse effects than did those in the short-term arm, with 76% v 50% of patients with at least one adverse event (P < .001), five versus one patient with grade 3 and 4 infections, and three versus zero patients discontinuing treatment because of unacceptable toxicity, respectively. There was no difference in OS between the two groups. CONCLUSION: Long-term rituximab maintenance therapy does not improve EFS, which was the primary end point of this trial, or OS, and was associated with increased toxicity.
RCT Entities:
PURPOSE:Rituximab maintenance therapy has been shown to improve progression-free survival in patients with follicular lymphoma; however, the optimal duration of maintenance treatment remains unknown. PATIENTS AND METHODS: Two hundred seventy patients with untreated, relapsed, stable, or chemotherapy-resistant follicular lymphoma were treated with four doses of rituximab monotherapy in weekly intervals (375 mg/m(2)). Patients achieving at least a partial response were randomly assigned to receive maintenance therapy with one infusion of rituximab every 2 months, either on a short-term schedule (four administrations) or a long-term schedule (maximum of 5 years or until disease progression or unacceptable toxicity). The primary end point was event-free survival (EFS). Progression-free survival, overall survival (OS), and toxicity were secondary end points. Comparisons between the two arms were performed using the log-rank test for survival end points. RESULTS: One hundred sixty-five patients were randomly assigned to the short-term (n = 82) or long-term (n = 83) maintenance arms. Because of the low event rate, the final analysis was performed after 95 events had occurred, which was before the targeted event number of 99 had been reached. At a median follow-up period of 6.4 years, the median EFS was 3.4 years (95% CI, 2.1 to 5.3) in the short-term arm and 5.3 years (95% CI, 3.5 to not available) in the long-term arm (P = .14). Patients in the long-term arm experienced more adverse effects than did those in the short-term arm, with 76% v 50% of patients with at least one adverse event (P < .001), five versus one patient with grade 3 and 4 infections, and three versus zero patients discontinuing treatment because of unacceptable toxicity, respectively. There was no difference in OS between the two groups. CONCLUSION: Long-term rituximab maintenance therapy does not improve EFS, which was the primary end point of this trial, or OS, and was associated with increased toxicity.
Authors: B D Cheson; S J Horning; B Coiffier; M A Shipp; R I Fisher; J M Connors; T A Lister; J Vose; A Grillo-López; A Hagenbeek; F Cabanillas; D Klippensten; W Hiddemann; R Castellino; N L Harris; J O Armitage; W Carter; R Hoppe; G P Canellos Journal: J Clin Oncol Date: 1999-04 Impact factor: 44.544
Authors: Chadi Nabhan; Nicholas J Ollberding; Dana Villines; Brian C-H Chiu; Donne Bennett D Caces; Tina V Valdez; Michele Ghielmini; Shu-Fang Hsu Schmitz; Sonali M Smith Journal: Leuk Lymphoma Date: 2013-11-01
Authors: M Federico; U Vitolo; P L Zinzani; T Chisesi; V Clò; G Bellesi; M Magagnoli; M Liberati; C Boccomini; P Niscola; V Pavone; A Cuneo; G Santini; M Brugiatelli; L Baldini; L Rigacci; L Resegotti Journal: Blood Date: 2000-02-01 Impact factor: 22.113
Authors: John D Hainsworth; Sharlene Litchy; Don W Shaffer; Van L Lackey; Manuel Grimaldi; F Anthony Greco Journal: J Clin Oncol Date: 2005-01-18 Impact factor: 44.544
Authors: John D Hainsworth; Sharlene Litchy; Howard A Burris; Daniel C Scullin; Steven W Corso; Denise A Yardley; Lisa Morrissey; F Anthony Greco Journal: J Clin Oncol Date: 2002-10-15 Impact factor: 44.544
Authors: Michele Ghielmini; Shu-Fang Hsu Schmitz; Sergio B Cogliatti; Gabriella Pichert; Jörg Hummerjohann; Ursula Waltzer; Martin F Fey; Daniel C Betticher; Giovanni Martinelli; Fedro Peccatori; Urs Hess; Emanuele Zucca; Roger Stupp; Tibor Kovacsovics; Claudine Helg; Andreas Lohri; Mario Bargetzi; Daniel Vorobiof; Thomas Cerny Journal: Blood Date: 2004-02-19 Impact factor: 22.113
Authors: N L Berinstein; A J Grillo-López; C A White; I Bence-Bruckler; D Maloney; M Czuczman; D Green; J Rosenberg; P McLaughlin; D Shen Journal: Ann Oncol Date: 1998-09 Impact factor: 32.976
Authors: Brad S Kahl; Fangxin Hong; Michael E Williams; Randy D Gascoyne; Lynne I Wagner; John C Krauss; Thomas M Habermann; Lode J Swinnen; Stephen J Schuster; Christopher G Peterson; Mark D Sborov; S Eric Martin; Matthias Weiss; W Christopher Ehmann; Sandra J Horning Journal: J Clin Oncol Date: 2014-08-25 Impact factor: 44.544
Authors: C Madsen; M R Clausen; T L Plesner; A Pasanen; T Kuismanen; H H Bentzen; J M Jørgensen; I B Sillesen; B M Himmelstrup; D Rønnov-Jessen; K R Jensen; A M Pettinger; M Ludvigsen; S Leppä; F A d'Amore Journal: Blood Adv Date: 2018-07-10
Authors: Alden A Moccia; Christian Taverna; Sämi Schär; Anna Vanazzi; Stéphanie Rondeau; Felicitas Hitz; Walter Mingrone; Thomas Pabst; Lidija Cevreska; Auro Del Giglio; Johann Raats; Daniel Rauch; Daniel A Vorobiof; Andreas Lohri; Céline Ruegsegger; Christine Biaggi Rudolf; Corinne Rusterholz; Stefanie Hayoz; Michele Ghielmini; Emanuele Zucca Journal: Blood Adv Date: 2020-12-08
Authors: Cara A Rosenbaum; Sin-Ho Jung; Brandelyn Pitcher; Nancy L Bartlett; Sonali M Smith; Eric Hsi; Nina Wagner-Johnston; Sachdev P Thomas; John P Leonard; Bruce D Cheson Journal: Br J Haematol Date: 2019-02-05 Impact factor: 6.998
Authors: Nathan H Fowler; Felipe Samaniego; Wojciech Jurczak; Nilanjan Ghosh; Enrico Derenzini; James A Reeves; Wanda Knopińska-Posłuszny; Chan Y Cheah; Tycel Phillips; Ewa Lech-Maranda; Bruce D Cheson; Paolo F Caimi; Sebastian Grosicki; Lori A Leslie; Julio C Chavez; Gustavo Fonseca; Sunil Babu; Daniel J Hodson; Spencer H Shao; John M Burke; Jeff P Sharman; Jennie Y Law; John M Pagel; Hari P Miskin; Peter Sportelli; Owen A O'Connor; Michael S Weiss; Pier Luigi Zinzani Journal: J Clin Oncol Date: 2021-03-08 Impact factor: 44.544